Targeted EGFR nanotherapy offers a promising approach to NSCLC management in the context where traditional ChT has limited efficacy in treating NSCLC and often causes significant side effects by its non-specific nature. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.